跳至主要内容
临床试验/NCT05613114
NCT05613114已完成不适用

Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

European University of Lefke1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2020年8月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
8
试验地点
1
主要终点
Timed 25-foot Walk Test

研究概览

简要总结

There are limited but encouraging results supporting the use of dalfampridine in patients with hereditary spastic paraplegia. The investigators aimed to investigate the effects of dalfampridine on walking speed, muscle length, spasticity, functional strength, and functional mobility in patients with hereditary spastic paraplegia. In this triple-blinded, randomized, placebo-controlled trial, 4 patients with hereditary spastic paraplegia received dalfampridine (10 mg twice daily) plus physiotherapy (2 times per week), and 4 patients received placebo plus physiotherapy for a total duration of 8 weeks. The assessor and treating physiotherapists, and patients were masked to the group allocation. The primary outcome was Timed 25-foot Walk Test at the end of the 8-week treatment. The secondary outcome measures were functional mobility, functional muscle strength, muscle length, and spasticity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosis of Hereditary Spastic Paraplegia at least 1 year ago

排除标准

  • Having another neurological disorder
  • An orthopedic deformity in the lower extremity
  • Having a serious cognitive impairment

研究组 & 干预措施

Medication

Experimental

Dalfampridine plus physiotherapy

干预措施: Dalfampridine 10 MG (Drug)

Medication

Experimental

Dalfampridine plus physiotherapy

干预措施: Physiotherapy (Behavioral)

No Medication

Placebo Comparator

Placebo plus physiotherapy

干预措施: Placebo (Drug)

No Medication

Placebo Comparator

Placebo plus physiotherapy

干预措施: Physiotherapy (Behavioral)

结局指标

主要结局

Timed 25-foot Walk Test

时间窗: Change from baseline to week 8

The Timed 25-foot walk test (T25FW) is considered the "best characterized objective measure of walking disability and can be used across a wide range of walking disabilities". For the T25-FW, patients were instructed to walk as fast as they could in a safemanner along amarked 25-foot course. The time in seconds to complete each test was recorded, and the test was immediately repeated.

次要结局

  • Sit to Stand Test(Change from baseline to week 8)
  • Timed Up and Go test(Change from baseline to week 8)
  • Modified Ashworth Scale(Change from baseline to week 8)
  • Muscle Length Measurement(Change from baseline to week 8)

研究者

发起方
European University of Lefke
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ferda Selcuk

Assist Prof. Dr.

European University of Lefke

研究点 (1)

Loading locations...

相似试验